Ravi Thadhani, MD, MPH
Year elected: 2008
Current membership category: Active
Chief Academic Officer & Professor of MedicinePartners HealthCare & Harvard Medical School
800 Boylston Street, 11th Floor
Somerville, MA 02145
United States of America
Our focus is to bring novel therapies and diagnostics to patients with renal failure in hopes to improve outcomes. We are currently focused on the cardiovascular and infectious consequences of defective vitamin D signaling in subjects with renal failure. Our team has performed several hypothesis-generating observational studies suggesting that therapy with activated vitamin D sterols is associated with improved survival among patients with renal failure. In addition, we have carried out a series of in-vivo studies in rodents which suggests that activated vitamin D sterols prevent the progression of cardiac hypertrophy and heart failure via inhibition of renin-angiotensin pathway and other pathways. Based on these observational human studies and in-vivo rodent experiments, we have initiated a multicenter randomized trial to test our hypothesis in humans. Our aims are not only to uncover specific cardiac and infectious mechanisms of survival related to altered vitamin D metabolism, but also to directly test our hypotheses in humans.
Cedars-Sinai Medical Center (Primary)
Robin Mark Shaw, MD, PhD is the representative at this institution.